Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ACIU Ac immune says its NLRP3 inhibitor Aci-19764 shows positive preliminary Phase 1 findings, including reported safety/tolerability and confirmed CSF penetration, with full Phase 1/1B results expected in H1 2027.
AC Immune says preliminary Phase 1 data for its NLRP3 inhibitor ACI-19764 are positive, with no further details on the findings supplied in the alert.